Castle Biosciences announces new data on TissueCypher test

Castle Biosciences (CSTL) announced that new data demonstrating the personalized risk stratification provided by its TissueCypher Barrett’s Esophagus test will be shared via a podium presentation at the American Foregut Society’s, AFS, 2025 Annual Meeting, taking place Sept. 11-13, 2025, in Dallas. “The findings being presented at AFS underscore the importance of moving beyond standard pathology when assessing progression risk in patients with Barrett’s esophagus,” said lead study author Caitlin C. Houghton, M.D., board-certified foregut surgeon at Keck Medicine of USC in Los Angeles. “TissueCypher provides an added level of precision that is designed to reveal high-risk patients who might otherwise be overlooked, potentially enabling personalized surveillance and treatment strategies aimed at reducing their chances of developing esophageal cancer.”